Expiry of subscription period and last trading day for subscription rights in the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN OR SUCH OTHER JURISDICTIONS WHERE THE OFFERING AND SALE OF THE NEW SHARES AND THE SUBSCRIPTION RIGHTS IS RESTRICTED BY LAW.

The period for trading in the subscription rights (DIAG S) in DiaGenic ASA's fully underwritten rights issue expires at 16:30 (CET) today, 31 March 2014. Further, the subscription period in the rights issue expires at 17:30 (CET) today, 31 March 2014.

Any subscription rights that are not sold prior to 16:30 (CET) today, or used to subscribe for new shares in the rights issue, prior to 17:30 (CET) today, will lapse without compensation to the holder and cease to carry any value.

Holders of subscription rights (whether granted or acquired) must, in order to subscribe for new shares, submit a correctly completed subscription form by mail, fax or email to Arctic Securities ASA, (fax no. +47 21 01 31 36, settlement@arcticsec.no).

Subscribers who are Norwegian citizens may also subscribe for shares through the VPS online subscription system or by following the link on www.diagenic.com or www.arcticsec.no, which will direct the subscriber to the VPS online system.

The information in this notice is not complete. For further information see Prospectus dated 14 March 2014 which is available online at www.diagenic.com and www.arcticsec.no. The Prospectus can also be obtained physically from the Manager.

The Manager:

Arctic Securities ASA

P.O. Box 1833 Vika

Haakon VII's gt. 5

0123 Oslo

Norway

www.arcticsec.no

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com